Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Category: Pharma Industry
Drugmakers Xellia Pharmaceuticals and Ascend Laboratories will refund 340B providers for some products following ceiling price recalculations, according to notices [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Kalderos, the drug industry vendor behind two 340B claims data submission platforms which support 340B rebates, will file an updated [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
AstraZeneca will discontinue a certain bottle dosage of its breast cancer drug Truqap (capiversatib) by the end of the year, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Belgium pharmaceutical giant UCB is extending its 340B contract pharmacy restrictions to all federal grantees and adding new data submission [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A New Jersey-based drugmaker announced this week that beginning in December, its 340B contract pharmacy restrictions will apply to Health [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A Washington state hospital on Tuesday became the fifth provider to sue the federal government for authorizing Johnson & Johnson [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
An organization that describes itself as being “comprised of dozens of national, public health, patient advocacy and multicultural organizations,” but [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The growth in total 340B purchases last year was largely a result of drugmaker price increases and broader healthcare trends, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The 340B drug discount program continued to be a hot topic for lobbyists in the third quarter of 2024, keeping [...] …
